10:11 AM EST - Avant Technologies Inc : Announced the formation of a groundbreaking Joint Venture and License Agreement aimed at revolutionizing a diabetes treatment through innovative stem cell and encapsulation technologies. The Joint Venture will now pursue a Research Collaboration Agreement to advance a proprietary differentiation process that efficiently converts stem cells into insulin-producing and regulating cells, forming the core of its therapy for type 1 and some insulin-dependent type 2 diabetes. Avant Technologies Inc
shares O.AVAI are trading unchanged at $0.39.
Full Press Release: https://www.baystreet.ca/quotedata/quote.aspx?ticker=AVAI&qmodStoryID=7045823087803229
